Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Giant Lymph Node Hyperplasia

abstract

  • These interim results strongly suggest that siltuximab is an effective treatment with favorable safety for the management of CD. An additional study is planned to fully evaluate safety and efficacy at the recommended dose of 12 mg/kg every 3 weeks.

publication date

  • August 10, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2009.27.2377

PubMed ID

  • 20625121

Additional Document Info

start page

  • 3701

end page

  • 8

volume

  • 28

number

  • 23